Genprex Publishes Clinical Data From Phase 1 Portion Of Acclaim-1 Clinical Trial Evaluating REQORSA Immunogene Therapy In Non-Small Cell Lung Cancer At 2023 ASCO Annual Meeting
Portfolio Pulse from Benzinga Newsdesk
Genprex published clinical data from the Phase 1 portion of the Acclaim-1 clinical trial evaluating REQORSA immunogene therapy in non-small cell lung cancer at the 2023 ASCO Annual Meeting. The combination of REQORSA and Tagrisso was well tolerated at all three dose levels, with encouraging evidence of efficacy observed.
May 25, 2023 | 9:08 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Genprex's positive Phase 1 data for REQORSA immunogene therapy in non-small cell lung cancer may boost investor confidence and stock price.
The positive Phase 1 data for Genprex's REQORSA immunogene therapy in non-small cell lung cancer indicates that the therapy is well tolerated and shows promising efficacy. This news may increase investor confidence in the company's product pipeline and lead to a short-term increase in the stock price.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100